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High concentrations of IL-2 in vitro can induce phenotypically heterogeneous
subpopulations oflymphocytes to mediatenonspecificlysisofabroad arrayofmalig-
nant cells (1-4). Althoughheterogeneous in phenotype, and thuspotentially hetero-
geneous in character and function, IL-2-induced cytolytic effector cells have been
generically termed lymphokine-activated killer (LAK)' cells (1). Administration of
high-dose IL-2 in vivo has been shown to similarly induce the activation of LAK
cells in vivo (5, 6), as well as to induce the proliferation of host lymphocytes (7),
the secretion oflymphokines (8, 9), and the regression ofsome malignant tumors
(5, 6, 10). Thecell populations andprecise cellular mechanisms responsiblefor tumor
regression invivo are ill defined. However, it is likely that themechanismsby which
IL-2 induces tumor regression will prove to vary according to the clinical circum-
stances, and will include the direct lysis oftumor cells by LAK cells, the primary
or secondary induction ofcytokines such as interferon or tumornecrosis factor, and
the augmentation of autochthonous tumor-specific immunity.
Regardless ofthe mechanism oftumor regression, toxicity has been amajorlimi-
tation forthe therapeutic use ofIL-2 against human malignancy (10, 11). The most
pronounced toxicity has been a vascular leak syndrome (10-13). However, hemato-
logical, renal, hepatic, and neurological abnormalities have also been observed and
limit the amount of IL-2 that can be administered (10-13). The proximate cause
oftoxicity is poorly defined but may include lymphoid hypertrophy with impinge-
ment upon adjacent tissue, secretion ofdeleterious lymphokines, and/or direct lysis
of normal tissue by promiscuously cytolytic cells (14-17).
Determination ofthecell populations andclarification ofthe precise mechanisms
responsible for both tumor regression and toxicity might suggest measures to aug-
ment efficacy and limit toxicity. For example, if toxicity is largely attributable to
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a distinct lymphocyte subset, suppression or deletion of that subset might abrogate
toxicity without impeding antitumor activity.
Although the phenotype of LAK cells mediating in vitro cytolytic activity has
been extensively evaluated, few studies have examined the phenotype of cells medi-
ating in vivo efficacy and toxicity, and general principles as to the mechanism(s)
ofeffect of high-dose IL-2 in vivo have yet to evolve. In vitro, in most circumstances
LAK cells with an NK-like phenotype are the predominant effector cells of LAK
cell-mediated cytolytic reactivity (18-20). However, in vivo, two reported studies
assessing the phenotype of cells mediating the therapeutic efficacy of high-dose IL-2
have demonstrated that lymphocytes expressing the Lyt-2' T cell phenotype are
the predominant effector cells against an established MCA sarcoma and a B16 mela-
noma cell transfected with class I MHC antigens (21, 22) . AsialOGM, (ASGM-1+)
cells have been shown to contribute to the therapeutic efficacy of IL-2 against MCA
sarcoma soon after implantation, indicating a potential role for cells with an NK
phenotype. However, once tumor had become established, ASGM-l' cells had no
detectable role in mediating tumor regression induced by IL-2 (21). By contrast,
in the single reported study assessing the phenotype of cells mediating toxicity of
high-dose IL-2 in vivo, toxicity was diminished by in vivo depletion of ASGM-l'
cells (23). These results suggest that the toxicity of IL-2 may be mediated primarily
by NK cell populations expressingthe ASGM-1 determinant (24). However, ASGM-1
has also been identified on lymphocyte populations other than NK cells, including
cytotoxic T cells(25), thymus cells (26), and activated macrophages (27), and a sub-
stantial role for such cells was not ruled out.
The current studies were designed to further delineate which lymphocyte popula-
tions are responsible for the lethal toxicity of high-dose IL-2 and which lymphocyte
populations are responsible for therapeutic efficacy. The model chosen for study was
the therapy ofan established, disseminated Friend virus-induced leukemia, termed
FBL-3, in syngeneic C57BL/6 mice. We had previously demonstrated that estab-
lished FBL-3 leukemia could be cured by high-dose IL-2 (6), but that the therapeutic
efficacy was greatly compromised by IL-2-induced toxicity. The initial current studies
revealed that high-dose IL-2 administered in vivo induced the proliferation of heter-
ogeneous lymphocyte populations including Lyt-2' T cells, L3T4' T cells, NK
cells, and B cells. The results of subsequent toxicity and therapy studies revealed
that the lethal toxicity of high-dose IL-2 was attenuated by the in vivo infusion of
antibody to NK-1.1 but not Lyt-2 or L3T4. By contrast, the therapeutic efficacy of
high-dose IL-2 was markedly reduced by infusion of antibody to Lyt-2 and L3T4
but not NK-1.1 . Thus, for the therapy of established, disseminated murine leukemia
with high-dose IL-2, the lymphocyte subpopulation that mediates toxicity is distinct
and separable from the lymphocyte subpopulations required for tumortherapy. The
ramifications of these results for IL-2 therapy of human malignancy are discussed.
Materials and Methods
Interleukin 2.
￿
Human rIL-2, generously provided by Hoffmann-LaRoche, Inc. (Nutley,
NJ), was diluted in HBSS containing 1% pathogen-free syngeneic mouse sera to provide
a specific activity of 106 units of IL-2 per milliliter as determined by a standard CTLL-2
proliferative assay (28).
Mice.
￿
Female C57BL/6 (B6) and BALB/c mice, 6-12 wk old, were obtained from ThePEACE AND CHEEVER
￿
163
Jackson Laboratories (Bar Harbor, ME) and BALB/c-nu/nu mice, 6-12 wk old, were obtained
from the Fred Hutchinson Cancer Research Center (Seattle, WA).
Tumor Cell Lines.
￿
FBL-3 (FBL), a Friend virus-induced leukemia of B6 origin was sub-
cloned and maintained by in vivo passage. YAC-1, an NK-sensitive Moloney virus-induced
lymphoma of A/Sn origin was maintained by in vitro passage in our laboratory.
Hybridomas andAntibody Preparations.
￿
Ascites containing mAb against NK-1.1 (from the
hybridoma PK136, a gift ofGloria Koo of Merck Sharp and Dohme, Inc., Rahway, NJ [29]),
Lyt-2 (from the hybridoma 2.43, obtained from American Tissue Culture Collection, Rock-
ville, MD [30]), L3T4 (from the hybridoma GK1.5, a gift ofFrank Fitch, University of Chicago,
Chicago, IL [31]), and murine IL-2-R (from the hybridoma 7D4, a gift ofTom Malek, Univer-
sity of Miami, Miami, FL (321) were prepared by injecting hybridomas intraperitoneally
into pristane-primed BALB/c-nu/nu mice. FITC-conjugated anti-Lyt-2 and antiThy-1.2 mAb
were purchased from Becton Dickinson Immunocytometry Systems (Mountain View, CA);
FITC-conjugated goat anti-rat IgG was purchased from Tago, Inc. (Burlingame, CA) ; and
F(ab')2 fragments of FITC-conjugated rabbit anti-mouse IgG were purchased from Zymed
Laboratories, Inc. (San Francisco, CA).
Immunofluorescent Cell Staining andFlow Cytometry.
￿
Spleen cells depleted of RBC by hypo-
tonic lysis were washed and resuspended at 10' cells/ml in HBSS. All staining steps were
performed at 4°C for 45 min. Thy-1 cells were labeled with FITC-conjugated antiThy-1 mAb.
Lyt-2' cells were labeled with FITC-conjugated anti-Lyt-2 mAb. L3T4' cells were labeled
with mAb GK1.5 and a second-step FITC-conjugated goat anti-rat IgG. sIg' cells were la-
beled with FITC-conjugated rabbit anti-mouse IgG. NK-1.1' cells were labeled with anti-
NK-1.1 and a second-step FITC-conjugated rabbit anti-mouse IgG. IL-2-R-bearing cells were
labeled with FITC-conjugated anti-IL-2-R mAb 7D4. Cytometric analyses were performed
with a cytofluorograph (model 50H) interfaced to a model 2150 computer (Ortho Diagnostics
Systems, Westwood, MA). Excitation was achieved with a laser power of400 mW at 488 nm.
FITC fluorescence was measured at 520 to 540 nm (DF 575; Omega Optical Co., Brattle-
boro, VT). Cells were distinguished as either small or large cells on the basis of the degree
of forward light scatter.
In Vivo Lymphocyte Subset Depletion.
￿
Ascites preparations ofPK136, 2 .43, and GK1.5 mAb
were titered in vivo for their ability to deplete NK-1.1', Lyt-2', and L3T4' lymphocyte
subsets, respectively, and amounts found to be effective were used in subsequent experiments.
The ability of antibodies to deplete the designated lymphocyte subset was established by im-
munofluorescent labeling and functional assay of the targeted lymphocyte subset 2 to 3 d
after intraperitoneal administration of antibody. In vivo depletion with mAb GK1.5 ascites
preparation (200 g1 i.p. on two successive days) markedly reduced cells, which could be
identified by two-step immunofluorescence. In vivo depletion with mAb 2.43 (100 41 i.p.)
markedly reduced cells that could be identified with a FITC-conjugated anti-Lyt-2 antibody
that binds to the Lyt-2 determinant in the presence of the mAb 2.43. In vivo depletion of
Lyt-2' cells with mAb 2.43 was also shown to abrogate subsequent in vitro generation of
allospecific CTL as demonstrated by the failure of Lyt-2-depleted B6 splenocytes stimulated
for 5 d with irradiated BALB/c splenocytes to lyse BALB/c Con A-induced lymphoblasts
during a 4-h "Cr-release assay. Depletion of NK-1.1' cells with mAb PK136 (100 ul i.p.) re-
duced cells, which could be identified by FITC-conjugated PK136 and markedly reduced
the ability of spleen cells from normal mice or mice primed for 24 h with 100 ttg poly(I:C)
to lyse the NK-sensitive target YAC-1 in an 18-h "Cr-release assay.
Results
High-Dose IL-2 InducestheProliferation ofHeterogeneousLymphocyte Subsets In Vivo
￿
Nor-
mal C57BL/6 (B6) mice were treated with IL-2 200,000 U i.p. three times a day
for 5 d and the number and phenotype of resultant lymphocytes determined. Similar
to previous reports (7), high-dose IL-2 induced marked hypertrophy of the spleen
and lymph nodes as well as lymphocytec infiltration of the liver and lungs. As an
example, in a representative experiment depicted in Fig. 1, IL-2 induced a 3-fold164
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increase in the total number of spleen cells and a 12-fold increase in the number
of large spleen cells, whichpresumably represented a measure ofactivatedandprolifer-
atinglymphoid cells. The phenotypes of the cells expanded by IL-2 were examined
and shown to be heterogeneous . Thus, Thy-1+ and Thy-1- spleen cells each in-
creased in number, 4.6-fold and 2.5-fold, respectively (Fig. 1 A). Within theenlarged
cell population expanded by IL-2 (dark area in Fig. 1), the majority of cells (89%)
expressed the Thy-1 determinant. Increases occurred in all lymphocyte subsets ex-
amined, including: both Lyt-2+ and L3T4+ T cells; mature NK cells (NK-1.1 +);
and B lymphocytes (Ig+ ), with the largest proportionate increase occurring within
the NK-1.1 ` and Lyt-2+ subsets of enlarged lymphocytes (Fig. 1 B) .
It is unknown as to what extent cellular proliferation was a result of direct IL-2
stimulation of IL-2-R-bearing cells versus indirect effects of IL-2 consequent to the
induction of the secretion of additional growth factors. The latter is a possibility
since only a minority of cells recovered from the spleens of IL-2-treated animals
expressed receptors for IL-2 (Table I).
Lymphocyte Subset Depletion in Mice Treated with High-Dose IL-2.
￿
To determine the
contribution ofspecific lymphocyte subsetsto thetoxicity and the therapeutic efficacy
ofIL-2, subsets were selectively depleted in vivo by administering antibody to specific
subsets before administering IL-2. Preliminary experiments confirmed previous
reports (21, 33) that antibody to Lyt-2, L3T4, or NK-1 .1 could specifically deplete
thenominated subset from normal mice. Efficacy ofdepletion was confirmedby use
of both phenotypic and functional analyses as detailed in Materials and Methods.
Before examining the effect of lymphocyte subset depletion on the toxicity and
efficacy of IL-2, it was necessary to establish that subsequent IL-2 administration
did not substantially reversethe effects ofsubset depletion. Thus, cohorts of antibody-
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FIGURE 1.
￿
High-dose IL-2 induces theprolifer-
ationofheterogeneous lymphocyte subsetsin vivo.
B6 mice were injected three times perday with
humanrIL-2, 200,000 U i.p. in HBSS or HBSS
alone (0.2 ml/dose) for 7 d. Animals were then
sacrificed andspleen cells enumerated.Cellswere
stained for surface expression of Thy-1, Lyt-2,
NK-1.1, L3T4, and IgG and analyzed by FRCS
as described in MaterialsandMethods. Blackbars
represent the total number of large cells which
expressedeach determinant and open bars rep-
resent the total number of small cells whichex-
pressed each determinant.PEACE AND CHEEVER
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TABLE I
Induction of IL-2 Receptors by High-Dose IL-2 Treatment
IL-2-R' :
In vivo IL-2. ￿Small cells
￿
Large cells
-
￿
0.7
￿
1 .2
+
￿
5.1
￿
18 .1
B6 mice were treated with no IL-2 or high-dose IL-2, 200,000 U i.p. three
times per day for 7 d.
Spleen cells were harvested and analyzed by FACS for IL-2-R expression as
described in Materials and Methods.
depleted mice were treated with IL-2 200,000 U i.p. three times a day for 7 d, then
lymphocyte subsets were quantified by immunofluorescent analysis. Resultsdemon-
strated (Table II) that lymphocyte subsets depleted before IL-2 therapy remained
substantially depleted after 7 d ofIL-2 therapy. In most experimentsin mice treated
with IL-2, the reduced number of targeted lymphocytes in spleen was offset by a
corresponding increase in the number oflymphocytes in the remainingsubsets, with
little change in the total IL-2-induced increase in lymphocyte number. As an ex-
ample, in a representative experiment, IL-2 at a dose of 200,000 U three times per
day for 7 d increased the total number of spleen cells from 9 x 107 to 25 x 107.
Treatment with anti-Lyt-2 followed by IL-2 resulted in a 92% decrease in Lyt-2+
cells with a concurrent 14.1% increase in NK-1.1+ cells and no significant differ-
ence in total splenocyte number compared with spleens obtained from mice treated
with IL-2 alone. Conversely, treatment with anti-NK-1.1 followed by IL-2 resulted
in a 78% decrease in NK-1 .1 + cells with a concurrent 29% increase in Lyt-2+ cells
compared with IL-2 alone.
The Lethal Toxicity ofHigh-Dose IL-2 Is Attenuated by the In Vivo Depletion ofNK-1.1
Cells but not Lt-2+ Cells or L3T4+ Cells.
￿
The contribution of Lyt-2+, L3T4+, and
NK-1.1 + lymphocyte subsets to the toxicity of high-dose IL-2 was determined by
selectively eliminatinglymphocyte subsets before the administration of apotentially
TABLE II
Lymphocyte Subset Depletion in Mice Treated with IL-2
' B6 mice were injected intraperitoneally with the indicated antibody as described
in Materials and Methods then treated with IL-2, 200,000 U i.p. three times
per day for 7 d.
$ After IL-2 therapy animals were killed and spleen cells were stained for ex-
pression of the indicated determinant and analyzed by FACS as described in
Materials and Methods. Results are presented as the percent ofpositive cells .
Antibody in vivo' Lymphocyte subset Percent positivel
None Lyt-2' 9.6
Anti-Lyt-2 Lyt-2 * 0.8
None L3T4' 35.6
Anti-L3T4 L3T4' 3.1
None NK-1' 19.6
Anti-NK-1 .1 NK-l' 5.3166
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lethal regimen of high-dose IL-2. Thus, B6 mice were injected with antibody against
the Lyt-2, L3T4, or NK-1.1 determinants. Mice were then treated with IL-2 200,000
U three times per day until all mice in an undepleted control groups had expired
from the toxic effects ofIL-2. Results (Fig. 2) demonstrated that by day 10 all control
mice had died from IL-2 . Depletion of NK-1.1 cells before IL-2 treatment markedly
reduced the number of mice that expired from an otherwise lethal regimen of IL-2
and allowed 44% of mice to survive the LD100 of IL-2. By contrast, prior depletion
of L3T4' or Lyt-2' cells did not detectably affect the toxicity in mice treated with
an identical regimen ofIL-2 . Mice that survived high-dose IL-2 as a result ofdepleting
NK-1.1 + cells developed signs of toxicity during IL-2 administration manifested by
varying degrees of ascites, tachypnea, and ruffled hair, but appeared well within 3
to 4 d after stopping IL-2 and continued to thrive during a 60-day post-therapy ob-
servation period. Although antibody to NK-1.1 decreased the toxicity of high-dose
IL-2, the attenuation of lethal toxicity was not absolute and could be overcome by
continued injections of high-dose IL-2 for two to four additional days (data not
presented) . The phenotype ofcellsmediating toxicity in this latter circumstance was
not analyzed.
The Therapeutic Efficacy ofHigh-DoseIL-2 AgainstDisseminated FBL-3Leukemia Is Re-
duced by In Vivo Depletion of either Lyt-2'
￿
Cells or L3T4+ ￿Cells but not NK-1.1 '
Cells.
￿
The role of Lyt-2', L3T4+, and NK-1 .1 + lymphocytes for the therapy of
FBL-3 leukemia with IL-2 was similarly examined. We had previously shown that
high-dose IL-2 injected from days 5 to 9 into C57BL/6 mice after injection on day
0 with 5 x 106 FBL-3 cells (as few as 10 FBL-3 cells will kill 100% of mice) could
cure approximately 50% ofmice (6). The optimum dose of IL-2 varied slightly from
experiment to experiment; and, the therapeutic effect of IL-2 was dose dependent
with decreasing doses curing a proportionately smaller percentage of mice. Increasing
the dose of IL-2 above the optimum level resulted in increased deaths from the tox-
icity of IL-2 and thus could not increase the proportion ofmice surviving long-term
tumor free and never cured 100% of mice.
In the current study (Fig. 3), B6 mice were injected on day 0 with 5 x 106 viable
FBL-3 cells. On day 3, mice were injected with anti-NK-1 .1, anti-Lyt-2, anti-L3T4,
or nonimmune sera as a control . On day 5, mice had palpable ascites and dissemi-
nated FBL and a total body burden of -109 FBL cells. Mice were then left untreated
FIGURE 2.
￿
The lethal toxicity of high-dose
IL-2 is attenuated by in vivo depletion ofNK-
1.1' cells but not Lyt-2' cells or L3T4' cells.
B6 mice were treated with anti-Lyt-2 mAb (n
= 16), anti-L3T4 (n = 10), anti-NK-1.1 mAb
(n = 16), or with nonimmune mouse sera-
indicated as "control" (n = 22), as described
in Materials and Methods. 2 d after initial ad-
ministration of antibody, mice were treated
with rIL-2, 200,000 U in 0.2 ml HBSS i.p.,
three times per day until all mice in the "con-
trol" group died from the toxic effects of high-
dose IL-2. IL-2 treatment was then terminated
and the percent of surviving animals in each
experimental group was monitored for a
follow-up period of2 mo. The graph represents
the combined results of four experiments.PEACE AND CHEEVER
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FIGURE 3. Abrogation of the therapeutic
efficacy ofhigh-doseIL-2 againstdisseminated
FBL leukemia by in vivo depletionof Lyt-2'
cells or L3T4' cells. B6 mice were injected
i.p. with 5 x 106 FBL tumor cells on day 0.
Cohorts of animals (14 per group) were in-
jected with normal mouse sera or ascites con-
taining anti-NK-1.1 or anti-Lyt-2 on day3or
anti-L3T4 on day 3 and day 4 as described
in Materials and Methods. Mice were then
treated with rIL-2, 50,000 U in HBSS or
HBSS alone, 0.2 ml i.p. three times per day
io
￿
-
￿
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￿
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￿
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￿
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￿
from day5throughday9. Percentage ofmice
surviving in each group from the time of
Days
￿
tumor inoculation is shown. The graph rep-
resentsthecombined results oftwo replicate
experiments.
or were treated with IL-2 (50,000 U three times a day) from days 5-9 . Mice receiving
no therapy all died by day 14, whereas 78% of mice treated with high-dose IL-2
alone were cured. Depletion of NK-1 .1' cells did not reduce the ability of IL-2 to
cure mice ofdisseminated leukemia. By contrast, depletion of either Lyt-2' or L3T4+
cells completely abrogated the curative effect of high-dose IL-2.
Discussion
The current study demonstrates that the NK-1.1' lymphocyte subset contributes
substantially to the lethal toxicity of high-dose IL-2 . The finding that specific in
vivo depletion of NK cells with the anti-NK-1 .1 antibody attenuates the lethal tox-
icityofIL-2, corroborates the demonstration by Gately et al. that depletion ofASGM-
l' cells reduces the toxicity of IL-2 (23), since both ASGM-1 and NK-1.1 are ex-
pressed by murine NK cells (24, 29). However, the use of antibody to NK-1.1 pro-
vides more direct evidence that phenotypic NK cells are major mediators oftoxicity,
since the NK-1.1 antigen appears to be more specific for NK cells than ASGM-1,
which has been identified on a variety of other cell types, including subsets of acti-
vated T cells (25), thymocytes (26) and macrophages (27).
The diminished toxicity resulting from the depletion of NK cells was not merely
the consequence ofa decrease in total lymphocyte number, since attenuation of tox-
icity achieved by in vivo removal of NK-1 .1' cells occurred despite a concurrent
compensatory increase in the numbers of cells in nondepleted lymphocyte subsets.
"Thus, IL-2-stimulated NK-1.1' cells appear to be intrinsically more toxic than the
other IL-2 responsive cell types examined in vivo.
The distinguishing attributes that account for the particularly toxic effects of NK
cells are undefined but potentially include both an increased propensity to lyse normal
tissue and/or propensity to secrete deleterious lymphokines. LAK cells have been
considered to be selectively lytic for malignant tumorcells (1). However, in addition
to lysing malignantly transformed cells, LAK cells have been reported to lyse a va-
riety of nontransformed cells, including Con A-stimulated lymphocytes (16), cul-
tured fibroblasts (15), primary explants of epithelial cells (14), endothelial cells (17),
as well as hapten-modified self (19).
LAK cells are heterogeneous in respect to precursor and effector phenotype, and168
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thus are likely to be heterogeneous in respect to target spectrum and the propensity
to lyse normal tissue. The two major phenotypic categories of LAK effector cells
derived from murine spleens are NK-like (NK-l') and T cell-like (Lyt-2+) cells that
are derived from Lyt-2 - and Lyt-2 + precursor cells, respectively (19, 20). Ballas et
al . (19) demonstrated that for lysis of haptenated self, differences exist between the
lytic efficacy ofmurine T cell-like LAK cells and NK-like LAK cells. In this circum-
stance, T cell-like LAK cells rather than NK-like LAK cells were most lytic. How-
ever, the results demonstrated that differences in lytic spectrum exist. In humans,
Sondel et al. (16) have confirmed that LAK cells derived from T cell-depleted PBL
cells, and therefore presumably highly enriched for NK-like LAK cells, are lytic
towards autologous lymphocytes, whereas Damle et al. (17) have shown that NK-like
LAK cells can lyse endothelial cells. Thus, NK-like LAK cells evidently can lyse
normal cells. However, differences in the spectrum of lytic activity against normal
tissues between LAK cell subsets have not yet been extensively evaluated, and whether
such differences are responsible for differences in toxicities is uncertain.
An alternative explanation for the predominant toxicity of the NK subset is the
potential preferential secretion of deleterious cytokines by IL-2-activated NK cells.
In vivo administration of high-dose IL-2 results in elevated levels of secondary
cytokines, such as TNFa and IFN-y (8, 9), which are each capable of mediating
lethal toxicity. Combined administration of IFN-y and TNFa has been shown to
induce toxic manifestations that are similar to those of high-dose IL-2 therapy, in-
cluding fever, hypotension, leukopenia, and renal, hepatic, and neurologic dysfunc-
tion (34). Moreover, TNFa has been implicated as the primary mediator of endo-
toxic shock (35), a condition characterized by vascular instability, fluid extravasation,
and hypotension similar to the vascular leak syndrome induced by IL-2 .
The primary in vivo source of IL-2-induced IFN-y or TNFa is unknown but may
be inherent within the NK cell population. In vitro, NK cells have been shown to
produce both IFN-y and a TNFa-like factor that is serologically crossreactive with
macrophage-derived TNF-a (36, 37). Furthermore, NK cells, but not T cells, are
induced by IL-2 to produce IFN-y during short-term culture in vitro (36). Thus,
NK cells may be preferentially stimulated by IL-2 in vivo to produce IFN-y and
TNF-a; and reduction of the toxicity of IL-2 by elimination of NK cells may result
from the removal of the major source of IFN or TNF or other, as yet undetermined,
cytokines . The in vivo ability of neutralizing antibody directed against specific
cytokines to attenuate IL-2-induced toxicity is being evaluated currently.
Depletion of NK cells with anti-NK-1.1 increased the LD-100 of IL-2 but did not
completely abrogate lethal toxicity, since animals treated with longer courses ofhigh-
dose IL-2 all eventually died (data not shown). Gately et al. (23) similarly observed
that anti-ASGM-1 delayed, but did not prevent, the occurence of lethal toxicity in
mice that received extended courses of IL-2. The nature of effector cells that mediate
the toxic effect of IL-2 in this circumstance was not examined. Either additional
cell subsets or reconstituted NK cells may be responsible for the delayed toxicity
of IL-2 following NK cell depletion. In vitro studies have demonstrated that IL-2
can promote the maturation of NK-1.1' cells from NK-1 .1 - precursors (33). Thus,
protracted IL-2 therapy may eventually reconstitute depleted populations of toxic
NK cells in vivo. On the other hand, cells potentially activated by IL-2 that are out-
side of the NK cell lineage, such as B cells, T cells, or monocytes may mediate the
lethal effect of protracted IL-2 in the absence of substantial numbers of NK cells.PEACE AND CHEEVER
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Both Lyt-2+ and L3T4+ cells, which were not dominant mediators oflethal tox-
icity, were required forexpressionofIL-2-induced therapyinthe FBL-3 model. Others
have demonstrated that Lyt-2+ cells are required for IL-2-induced regression ofes-
tablished macrometastaticMCA-induced sarcomas (21), and regression ofB16 mela-
noma-expressing class I MHC antigens (22). The mechanism by which Lyt-2+ cells
contribute to the therapeutic effects of IL-2 in the aforementioned models is un-
determined. In vitro, IL-2 can induce Lyt-2+ cells to become LAK effectors capable
of lysing a broad spectrum oftumors in a non-MHC-restricted manner, but also
can facilitate the generation and function ofspecifically immune Lyt-2+ cells capable
ofmediatingdestruction oftumor through specific recognition oftumor-associated
antigen presented byclass I MHC antigens. Although both specific and nonspecific
mechanisms might be operative during IL-2-induced tumor eradication, it is likely
that autochthonous tumor-specific T cell immunity is a predominant, ifnot essen-
tial component. Evidence for this view is taken from several sources. First, the cur-
rent observation that depletion ofNK-1.1+ cells did not diminish therapeutic efficacy
ofIL-2 impliesthat thenonspecific componentofIL-2 therapymightbeweak. Second,
in both the FBL-3 model and the MCA sarcoma model, delayed IL-2 therapy after
tumor implantation has been shown to be significantly more effective than therapy
immediately after tumor implantation (5, 6), implying that the evolution of a
host-tumor interaction is essential for successful therapy with IL-2. One likely
host-tumor interaction wouldbe theinduction ofspecific host antitumorimmunity.
Accordingly, mice cured of FBL-3 by high-dose IL-2 have been shown to contain
T cells specifically immune to FBL-3 (6). Third, in the MCA sarcoma model, Mul6
(21) has demonstrated that for the therapy ofestablished MCA sarcoma, weakly im-
munogenicsarcomas respondto IL-2, whereasnonimmunogenic sarcomas are refrac-
toryto the therapeutic effectsofIL-2 despitethe fact that immunogenic and nonim-
munogenic MCA sarcomas are lysed equivalently by LAK cells in vitro (21).
The principledifference identified betweennonimmunogenic andweakly immuno-
genic MCA sarcomas by Mulé was the expression ofclass I MHC antigens by the
immunogenic tumors but not bythe nonimmunogenic tumors (21). Neither expresses
class II MHC antigens. Therefore, only the weakly immunogenic MCA sarcomas
have the potential to be lysed by tumor antigen-specific MHC-restricted T cells.
The importance of expression of MHC antigens by tumor cells for elicitation of
therapeutic IL-2-induced responses was further established by Weber et al. (22) in
studies involvingtransfection ofMHC genes into B16 melanoma. Theydemonstrated
that expression ofclass I MHC rendered established B16 melanoma sensitive to IL-
2 therapy. In this circumstance, Lyt-2+ cells were also required for therapy.
In the current experiments, L3T4+ cells, as well as Lyt-2+ cells, were shown to
be required for thetherapeuticeffects ofIL-2. During thegeneration ofmost normal
immune T cell responses, L3T4+ T cells respond to antigen presented by class II
MHC antigen and provide T cell help, and Lyt-2+ T cells respond to antigen
presented by class I MHC antigens and provide for specific cytolytic reactivity (38,
39). Similarly, in the FBL-3-specific T cell response, the L3T4+ subset has been
shown to provide the majority ofhelp required for the generation of FBL-3 tumor-
specific Lyt-2+ cytolytic T cells; and direct cytolytic reactivity is mediated exclu-
sively by Lyt-2+ T cells (40). It is noteworthy that FBL-3 does not express class II
MHC antigens nor can such antigens be induced by IFN-y (41). Thus, L3T4+ T
cells that are restricted to recognizing antigen presented by class 11 MHC antigens170
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are incapable of directly recognizing FBL-3 cells; and, stimulation of L3T4' T cells
by tumor requires that tumor antigen be processed and presented by APCs, such
as macrophages (40). Since L3T4' T cells cannot directly lyse FBL-3 in an antigen-
specific fashion, and since IL-2-activated L3T4' cells constitute a minor subset of
nonspecific LAK cell effectors, as determined in in vitro studies, it is possible that
L3T4' cells in the current therapy study were requisite for the evolution of the ini-
tial host antitumor immunity rather than for the effector phase of IL-2-induced therapy.
Alternatively, immune L3T4' T cells might not be required for the initial IL-2-
induced antitumor response, but might be required for mediating a specific antitumor
response to eradicate the last remaining tumor cells potentially present long after
IL-2 therapy.
The implication in murine models that autochthonous tumor-specific T cell im-
munity may be a predominant component ofsuccessful therapy with high-dose IL-2
may be especially germane to the use of IL-2 for the treatment of human malignan-
cies. The observation that most fresh human tumors can be nonspecifically lysed
by LAK cells in vitro, whereas only a modest proportion of tumors can be induced
to regress by IL-2 in vivo implies that non-MHC-restricted lysis of tumors may
not be the essential component of IL-2-induced tumorregression in vivo. Moreover,
tumor typesthat have responded most consistently to IL-2-based regimens in humans
are those that have long been considered to be immunogenic in nature (i.e., mela-
noma and renal cell carcinoma [10, 11]). Therefore, autochthonous host antitumor
immunity may be required for response to high-dose IL-2 in humans. In the case
of human malignant melanoma, the tumormost extensively assessed for responsive-
ness to IL-2, lymphocytes obtained from melanoma tumor siteseither before or after
therapy with IL-2 predominantly express T cell determinants (42, 43) . Moreover,
T lymphocytes that specifically lyse autologous tumor cells have been cloned directly
from melanoma tumors, confirming the existence of autochthonous tumor-specific
T cells at the site of tumor that might be activated or induced to proliferate by ad-
ministration ofIL-2 in vivo (44). In the small number of patients examined to date,
only melanoma tumors expressing class II MHC antigens have responded to IL-2
(43), adding further credence to the possibility that MHC-restricted T cell responses
are necessary for effective therapy with IL-2 .
The implication that human tumors responding to IL-2 therapy may be immuno-
genic in the autochthonous host serves to focus attention on potential methods to
augment specific aspects of IL-2 therapy, as opposed to the current emphasis on
developing methods to augment nonspecific aspects. Finally, regardless of whether
or not T cells are required for the efficacy against the majority of human tumors,
for those human tumors in which the therapeutic effects of IL-2 are predominantly
mediated by T cells, the current study predicts that it should be possible to reduce
toxicity and increase the therapeutic index of IL-2 by selectively depleting NK cell
subsets.
Summary
In the current study we used the therapy ofestablished murine leukemia to iden-
tify the lymphocyte subsets responsible for toxicity and for therapeutic efficacy of
high-dose IL-2 . Initial results confirmed that high-dose IL-2 induces marked prolifer-
ation of a variety of host cells, including NK cells, Lyt-2' T cells, L3T4' T cells,and B cells. Infusion of antibody to NK-1.1 depleted NK-1.1 + cells in vivo and
greatly reduced the toxicity of IL-2, but did not decrease therapeutic efficacy. By
marked contrast, depletion of host T cells, either Lyt-2 + or L3T4+ , had no effect
on toxicity but greatly reduced therapeutic efficacy. The requirement for host T cells
for the curative effect ofIL-2 gives credence to the possibility that substantial efficacy
ofhigh-dose IL-2 against established malignancy may require existent host antitumor
immunity. Since the human tumors that have been shown to have the most substan-
tial responses to IL-2 (i.e., malignant melanoma and renal cell carcinoma) are those
long considered to be immunogenic in the autochthonous host, the current study
predicts that for these, as well as other immunogenic human tumors, it should be
possible to decrease the toxicity and thus increase the therapeutic index of IL-2 by
selectively depleting NK cells in vivo.
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